Intangible Assets

STIM appears to have some product-specific know-how and regulatory know-how typical of a medical device company, but the provided metrics do not show durable excess returns that would indicate a stronger peer moat.

Compared with larger medtech peers that often defend pricing through entrenched clinical evidence, broad installed bases, and brand recognition, STIM’s moat appears narrower and more dependent on product performance than on hard-to-replicate intangibles.

The negative TTM ROIC and ROCE suggest any intangible advantage is not yet translating into sustained economic profits, which weakens evidence of durable pricing power versus peers.

Switching Costs

The available data do not indicate high customer lock-in, and the negative TTM ROIC implies customers are not being monetized in a way that reflects strong retention economics.

Relative to peers with integrated workflows, consumables pull-through, or deep clinical embedding, STIM appears to face easier substitution because the evidence for embedded switching costs is limited.

Without clear evidence of long-duration contracts, proprietary integration, or high retraining costs, switching costs look modest and not strong enough to protect margins over 5–10 years.

Network Effects

There is no evidence in the provided data of a two-sided platform, data flywheel, or user-to-user network that would compound value over time.

Compared with peer businesses that benefit from ecosystem adoption or procedure-volume concentration, STIM does not appear to have a self-reinforcing network structure that raises retention or pricing power.

The company’s current profitability profile does not suggest network-driven scale benefits, so network effects are not a meaningful moat driver here.

Cost Advantage

The negative ROIC and ROCE indicate STIM is not currently converting capital into returns better than peers, which argues against a durable cost advantage.

Its asset turnover is reasonable, but without evidence of structurally lower manufacturing, distribution, or service costs than peers, efficiency alone does not establish a moat.

Compared with larger competitors that can spread fixed R&D, regulatory, and commercial costs across broader revenue bases, STIM appears less likely to sustain a cost edge.

Efficient Scale

STIM may benefit from some niche-market scale economics if its addressable segment is specialized, but the evidence does not show a protected market structure that limits peer entry.

Relative to dominant medtech platforms with large installed bases and broad channel reach, STIM’s scale appears insufficient to create strong industry-wide barriers.

The absence of positive excess returns suggests any efficient-scale benefit is not yet large enough to materially improve pricing power or long-run margin durability.

Overall Score

STIM’s moat appears weak versus peers because the available evidence shows no durable excess returns, limited switching costs, no network effects, and no clear cost or scale advantage strong enough to support sustained pricing power over 5–10 years.